CT
CRSP icon

Clearstead Trust’s CRISPR Therapeutics CRSP Stock Holding History

Clearstead Trust’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.56K Hold
102
– – ﹤0.01% 756
2026
Q1 		$4.85K Hold
102
– – ﹤0.01% 757
2025
Q4 		$5.35K Hold
102
– – ﹤0.01% 746
2025
Q3 		$6.61K Hold
102
– – ﹤0.01% 693
2025
Q2 		$4.96K Hold
102
– – ﹤0.01% 750
2025
Q1 		$3.47K Hold
102
– – ﹤0.01% 681
2024
Q4 		$4.01K Buy
+102
New +$4.82K ﹤0.01% 397
2024
Q3 		– Sell
-115
Closed -$6.21K – 420
2024
Q2 		$6.21K Hold
115
– – ﹤0.01% 378
2024
Q1 		$7.84K Hold
115
– – ﹤0.01% 362
2023
Q4 		$7.2K Hold
115
– – ﹤0.01% 354
2023
Q3 		$5.22K Buy
+115
New +$5.94K ﹤0.01% 381
2022
Q4 		– Sell
-170
Closed -$11K – 384
2022
Q3 		$11K Hold
170
– – ﹤0.01% 282
2022
Q2 		$10K Hold
170
– – 0.01% 149
2022
Q1 		$11K Buy
+170
New +$10.7K 0.01% 155
2020
Q1 		– Sell
-135
Closed -$8K – 177
2019
Q4 		$8K Buy
+135
New +$7.37K 0.01% 160

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Clearstead Trust's CRSP Position: Q2 2026 in Review

Clearstead Trust held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 102 shares worth $5.56K. The position accounts for ﹤0.01% of the portfolio, ranked #756.

Clearstead Trust first reported a position in CRSP in Q4 2019 and has held it in 15 quarters since. The position peaked at $11K in Q3 2022. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Clearstead Trust held 102 shares of CRISPR Therapeutics worth $5.56K as of Q2 2026.
  • Clearstead Trust left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Clearstead Trust's portfolio in Q2 2026, its #756 holding.
  • Clearstead Trust first reported a position in CRISPR Therapeutics in Q4 2019 and has held it in 15 quarters since.
  • Clearstead Trust's CRISPR Therapeutics position peaked at $11K in Q3 2022.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Clearstead Trust's 13F filing for Q2 2026, filed 6 Aug 2026.